Loading..

Gelesis Holdings, Inc. Announces Additional $15 Million Pre-Order for Plenity, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million

2022-06-21 10:30:00

Gelesis Holdings, Inc. announced that Ro has placed a $15 million pre-paid order for the company’s commercial product for weight management, Plenity®. This is in addition to previous Plenity pre-orders from Ro totaling $40 million. Gelesis launched the first wave of its national broad awareness media campaign for Plenity on January 31, 2022, which corresponded with record high levels of web traffic and prescription requests. Since the broad consumer launch, Plenity has become one of the most sought-after offerings on Ro’s platform. After a consultation with a licensed healthcare provider, if they qualify, individuals can be approved for a prescription within 24 hours. The treatment is then shipped directly to their home and arrives within 2 days, at $98 for a 28-day supply. Following the launch of the campaign, the number of individuals seeking a new prescription increased 140% during the first quarter to reach record highs. The company reported $7.5 million in net product revenue in the first quarter of 2022, a 142% increase over the first quarter 2021. Gelesis has also reported growth in the more traditional healthcare provider (HCP) channel following the launch of the campaign and the company expects consumer demand to continue to drive uptake. Notably 40-50% of these HCP prescriptions were requested by the consumer (the company’s baseline before the media campaign began was 25%). Plenity has the large addressable market of any prescription weight management approach, and 150 million American adults could qualify for treatment, including the tens of millions of Americans with a BMI between 25 and 30 who generally do not qualify for other prescription weight loss treatments. About 70% of Plenity members had never tried a prescription weight management product before, indicating Plenity is bringing new people into the category of prescription weight management products.

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P Global BMI Index

2022-06-20 00:00:00

Gelesis Holdings, Inc.(NYSE:GLS) added to S&P Global BMI Index

Gelesis Holdings, Inc. Presents at 7th Microbiome Movement Drug Development Summit, Jun-22-2022 03:30 PM

2022-06-15 18:00:00

Gelesis Holdings, Inc. Presents at 7th Microbiome Movement Drug Development Summit, Jun-22-2022 03:30 PM. Venue: Westin Boston Seaport District, 425 Summer St., Boston, Massachusetts, United States. Speakers: Bryan Jones, Senior Director.

Hanson Wade Limited, 7th Microbiome Movement Drug Development Summit, Jun 21, 2022 through Jun 24, 2022

2022-06-15 11:41:00

Hanson Wade Limited, 7th Microbiome Movement Drug Development Summit, Jun 21, 2022 through Jun 24, 2022. Venue: Westin Boston Seaport District, 425 Summer St., Boston, Massachusetts, United States.

Gelesis Holdings, Inc. has closed its Shelf Registration dated February 11, 2022 in the amount of $508.696819 million.

2022-06-07 00:00:00

Gelesis Holdings, Inc. has closed its Shelf Registration dated February 11, 2022 in the amount of $508.696819 million. Security Name: Common Stock Securities Offered: 132,857,109 Security Name: Warrants Securities Offered: 24,333,365

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

2022-06-04 15:00:00

Gelesis Holdings, Inc. presented new preclinical data showing weight loss and additional metabolic benefits in mice receiving a microbiota transplant from another group of mice, treated with one of the company’s proprietary hydrogels. These metabolic benefits occurred while both groups of mice, the donors of the microbiota transplant and the recipient mice, were on a high fat, high carbohydrate diet typically causing rapid weight gain, obesity, and diabetes. The findings were presented on June 4, 2022 at the American Diabetes Association’s annual conference.Gelesis’ superabsorbent hydrogels are inspired by the composition (cellulose structures holding water) and mechanical properties (elasticity or firmness) of ingested raw vegetables. They are taken by capsules with water before a meal to create a much larger volume of small, non-aggregating hydrogel pieces that act locally in the digestive system without adding any additional calories. One of the hydrogels is commercially available as Plenity® to aid in weight management; others that utilize the same platform technology are in clinical and preclinical studies. In April, Gelesis presented preclinical data at the World of Microbiome conference suggesting that adding superabsorbent hydrogel (Gel-B, an investigational candidate) to a high-fat “western-like” diet prevents unfavorable changes in the communities of gut bacteria associated with diet-induced weight gain. The study showed a striking effect on gut microbiota composition with enrichment of several key bacteria such as Akkermansia muciniphila, a bacterial species associated with gut health and weight loss. Importantly, an addible fiber (a modified cellulose), used as a positive control, did not support the growth of these species. This same type of modified cellulose is used to create Gelesis’ proprietary hydrogels. The difference in bacterial growth between the linear fiber and the 3-dimensional hydrogel suggests that the effects of the hydrogel on the microbiota are mainly mechanical (i.e. elastic response or firmness). In previous studies, administration of one of these hydrogels, in addition to a high-fat diet, blunted weight gain, reversed gut atrophy, improved metabolic parameters, and restored gut barrier. This new study aimed to investigate whether transferring the microbiota from Gel B-treated mice into the gut of mice fed a high fat, high carbohydrate, high cholesterol (HFHCC) diet for 10 weeks could alleviate the detrimental effects of their diet.The study used intestinal microbiota transfer (IMT) to investigate the functional role of the gut microbiota to explain the metabolic effects associated with Gel-B treatment. Metabolic disease was induced in two cohorts of mice (“Donors” and “Recipients”) via consumption of a high fat, high cholesterol, high carbohydrate diet for 10 weeks. Donors either continued HFHCC or were treated with HFHCC plus Gel-B for 6 additional weeks. Fecal samples were processed from Donors every other day during weeks 2-6 of treatment. Recipients received either intestinal microbiota transfer from Gel-B-treated or untreated Donors. Recipients receiving IMT from untreated Donors continued to gain weight, while Recipients receiving IMT from Gel-B treated Donors lost weight, despite the continued consumption of HFHCC. Treating the recipients with intestinal microbiota of Gel B treated donors also resulted in improvement in glycemic control.

Gelesis Holdings, Inc. Auditor Raises 'Going Concern' Doubt

2022-05-24 00:00:00

Gelesis Holdings, Inc. filed its S-1/A on May 24, 2022 for the period ending Dec 31, 2021. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08:30 AM

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 08:30 AM. Venue: Lotte New York Palace, New York City, New York, United States. Speakers: David Pass, COO & Chief Commercial Officer, Elliot Maltz, CFO & Treasurer, Yishai Zohar, Founder, President, CEO & Director.

Gelesis Holdings, Inc. Presents at Loop Capital Markets Technology, Media and Telecom Conference, Jun-01-2022

2022-05-18 20:05:00

Gelesis Holdings, Inc. Presents at Loop Capital Markets Technology, Media and Telecom Conference, Jun-01-2022 . Venue: Lotte New York Palace, New York City, New York, United States.

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

2022-05-12 20:30:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. For the year, the company expects net product revenues of $58 million, which reflects approximately a 400% increase over 2021.

Gelesis Holdings, Inc. Announces Auditor Changes

2022-05-10 20:40:00

On May 9, 2022, the audit committee of the Board of Gelesis Holdings, Inc. approved a resolution appointing KPMG LLP (KPMG) as company's independent registered public accounting firm to audit consolidated financial statements for the fiscal year ending December 31, 2022. KPMG served as the independent registered public accounting firm of Legacy Gelesis prior to the Business Combination. Accordingly, Marcum LLP (Marcum), CPSR’s independent registered public accounting firm prior to the Business Combination, was informed on May 9, 2022 that it would be replaced by KPMG as Gelesis' independent registered public accounting firm.

Gelesis Holdings, Inc. to Report Q1, 2022 Results on May 12, 2022

2022-05-09 10:00:00

Gelesis Holdings, Inc. announced that they will report Q1, 2022 results After-Market on May 12, 2022

Gelesis Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022

2022-05-09 10:00:00

Gelesis Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $117.289387 million.

2022-05-06 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $117.289387 million. Security Name: Common Stock Securities Offered: 22,997,919 Transaction Features: ESOP Related Offering

Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

2022-05-04 10:35:00

Gelesis presented results from the LIGHT-UP clinical trial for adults with overweight or obesity who have prediabetes or type 2 diabetes and were treated with either GS200 or placebo. Approximately 6 out of 10 adults treated with GS200 achieved clinically meaningful response to treatment (achieving at least 5% body weight loss), losing on average 11% of their body weight (~23 pounds) and an average reduction of 5.5 inches off their waist circumference. Approximately 1 out of 3 GS200-treated adults were “super responders,” losing at least 10% of their body weight and on average losing 13% (~30 pounds), or 7 inches off their waist circumference. The overall incidence of adverse events (AEs) in adults treated with GS200 was similar to the incidence of AEs in the placebo group. The detailed findings were presented at three poster presentations at the European Congress on Obesity 2022. Anti-obesity medications are prescribed in less than 2% of people with overweight or obesity in the US mainly due to concerns about the safety or tolerability of existing medications. There is a need for orally administered treatments that can induce clinically meaningful weight loss, with no significant increased safety risk, especially in people with type 2 diabetes or prediabetes since they typically face increased challenges losing weight and have higher risk of developing serious comorbidities. GS200 is an orally administered superabsorbent hydrogel taken by capsule with water 10 minutes before lunch and dinner and is designed to act mechanically in the gastrointestinal tract in order to induce satiety in patients with prediabetes and type 2 diabetes. Participants in LIGHT-UP were also instructed to follow a modestly reduced calorie diet along with moderate-intensity physical activity. In the GS200 group there was clear and early separation between responders and non-responders to treatment, and response to therapy could be predicted as early as 6 weeks of treatment.

Gelesis Holdings, Inc. announced delayed annual 10-K filing

2022-04-01 00:00:00

On 04/01/2022, Gelesis Holdings, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Gelesis Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

2022-03-24 20:00:00

Gelesis Holdings, Inc. provides revenue guidance for the full year 2022. The company estimates product revenue, net, of about $58 million in 2022.

Loop Capital Markets LLC, Loop Capital Markets Technology, Media and Telecom Conference, Jun 01, 2022 through Jun 02, 2022

2022-03-17 15:04:00

Loop Capital Markets LLC, Loop Capital Markets Technology, Media and Telecom Conference, Jun 01, 2022 through Jun 02, 2022. Venue: Lotte New York Palace, New York City, New York, United States.

UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022

2022-03-03 04:07:00

UBS Investment Bank, UBS Global Healthcare Conference, May 23, 2022 through May 25, 2022. Venue: Lotte New York Palace, New York City, New York, United States.

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $434.291987 million.

2022-02-11 00:00:00

Gelesis Holdings, Inc. has filed a Shelf Registration in the amount of $434.291987 million. Security Name: Common Stock Securities Offered: 132,938,108 Security Name: Warrants Securities Offered: 24,509,491

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

2022-01-31 11:50:00

Gelesis Holdings, Inc. provided revenue guidance for the year 2022. The company currently anticipates that its 2022 revenue will be approximately $58 million in its first year of a full launch.

Gelesis, Inc. Appoints Joy Bauer as Chief Nutrition Officer

2021-12-01 12:10:00

Gelesis, Inc. announced the appointment of Joy Bauer, MS, RDN, CDN, as Chief Nutrition Officer.

Gelesis, Inc. Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available

2021-12-01 12:10:00

Gelesis, Inc. announced that Plenity®, an FDA cleared weight management approach, is now broadly available across the United States to adults who meet the prescription criteria.

Gelesis, Inc. Receives $30 Million Plenity Order from Ro

2021-11-18 12:10:00

Gelesis, Inc. announced that Ro has placed a $30 million fully paid pre-order for the company's first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020, and demand quickly outpaced supply while Gelesis worked to construct a larger manufacturing facility. Gelesis' first commercial-scale manufacturing line at the facility is now complete and validated. As Gelesis' exclusive telehealth partner in the U.S., Ro provides patients with access to telehealth options for weight management including the ability to communicate with a healthcare provider and, if safe and appropriate, to receive a prescription for Plenity through myplenity.com and Ro's digital clinics. The telehealth experience complements in-person healthcare provider care (available through any provider and powered by GoGoMeds), making it easier for people to seek treatment on their own time and their own terms.

Gelesis, Inc. Auditor Raises 'Going Concern' Doubt

2021-11-09 00:00:00

Gelesis, Inc. filed its Annual on Nov 09, 2021 for the period ending Dec 31, 2020. In this report its auditor, KPMG LLP - Klynveld Peat Marwick Goerdeler, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Capstar Special Purpose Acquisition Corp., Gelesis, Inc. - M&A Call

2021-07-19 11:00:00

To discuss business combination agreement between Gelesis, Inc. and Capstar Special Purpose Acquisition Corp.

Gelesis, Inc. announced that it expects to receive $100 million in funding from Pacific Investment Management Company LLC, Pritzker/Vlock Family Office, Kennedy Lewis Investment Management LLC, China Medical System Holdings Limited, PureTech Health plc

2021-07-19 00:00:00

Gelesis, Inc. announced that it has entered into subscription agreements with certain investors for private placement of up to 10,000,000 class A shares at a price of $10 per share for gross proceeds of up to $100,000,000 on July 19, 2021. The transaction included participation from new and existing top tier investors and partners including private funds of Pacific Investment Management Company LLC, Pritzker/Vlock Family Office, Kennedy Lewis Investment Management LLC, China Medical System Holdings Limited, PureTech Health plc, and affiliates of the sponsor. Kennedy Lewis Investment Management LLC will invest $10,000,000 conditioned upon the closing of its $100,000,000 senior secured credit facility, which is subject to the completion of due diligence, final documentation, and customary closing conditions. Affiliates of the Sponsor will invest $35,000,000 in the transaction. The investors will acquire 7% stake in the company at a implied market value of $1,328,000,000. The transaction has been approved by the board of directors of the company. The transaction is expected to close in the fourth quarter of 2021, subject to the satisfaction of certain closing conditions. The company will issue securities pursuant to exemption provided under Section 4(a)(2) of the Securities Act.

Gelesis, Inc. entered letter of intent to acquire Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders for approximately $980 million in a reverse merger transaction.

2021-07-19 00:00:00

Gelesis, Inc. entered letter of intent to acquire Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders for $1.1 billion in a reverse merger transaction on April 15, 2021. Gelesis, Inc. entered into an agreement to acquire Capstar Special Purpose Acquisition Corp. from a group of shareholders on July 19, 2021. A maximum of approximately 109 million shares may be issued to holders of shares of Gelesis common stock, Gelesis options and Gelesis warrants in connection with the business combination. The transaction will provide up to $376 million in gross proceeds to the combined company from a combination of a $100 million common stock PIPE financing at $10.00 per share along with $276 million of cash held in Capstar’s trust account. The business combination agreement may be terminated by either CPSR or Gelesis if the closing has not occurred by January 18, 2022, subject to certain exceptions. On November 8, 2021, the parties entered into an amendment to the original business combination agreement which, among other things (i) adjusts the equity valuation of Gelesis from $900 million to $675 million (ii) increases the number of Earn Out shares available to be issued to Gelesis stockholders from 15 million to 23.5 million, (iii) provides for the issuance of 1.98 million additional Capstar Class A Shares to Gelesis stockholders, equal to the number of Capstar Class B Shares forfeited by the Sponsor and certain affiliates of the Sponsor in accordance with the Sponsor Letter Agreement Amendment and (iv) extends the termination date from January 18, 2022 to January 31, 2022. A maximum number of 96.03 million shares may now be issued to holders of shares of Gelesis common stock, options and warrants in connection with the business combination resulting in a total consideration of approximately $960 million. As of December 30, 2021, parties entered into second amendment which, among other things, removed the provisions relating to the issuance of 1,983,750 additional Capstar Class A Shares to Gelesis stockholders, equal to the number of Capstar Class B Shares forfeited by Capstar Sponsor Group LLC and certain affiliates of the Sponsor in accordance with the Amendment to Sponsor Letter Agreement entered into by Capstar and Gelesis on November 8, 2021. Upon completion, assuming no redemption, the Gelesis stockholders, will own 64.1%, PIPE investors will own 7.8%, CPSR public stockholders will own approximately 23.9% of the combined company. Upon completion of the transaction, the combined company’s securities are expected to be traded on the New York Stock Exchange (NYSE) under the symbol “GLS.” Following the consummation of the Business Combination, it is expected that the New Gelesis Board will consist of nine (9) directors, which will be divided into three classes (Class I, II and III) with each of Class I, II and III consisting of three directors. Capstar Board shall consist of a defined number of directors, among others. The transaction is subject to the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder relating to the Business Combination having been expired or been terminated and any other required regulatory approvals applicable to the transactions contemplated by the Business Combination Agreement having been obtained, registration statement being declared effective by the U.S. Securities and Exchange Commission, approval of CPSR and Gelesis shareholders, CPSR’s initial listing application with the New York Stock Exchange in connection with the transactions contemplated by the Business Combination Agreement having been approved, registration Statement / Proxy Statement shall have become effective and Capstar shall have at least $5,000,001 of net tangible assets. The transaction has been unanimously approved by the Boards of Directors of both Gelesis and CPSR. CPSR Board recommends that stockholders vote for the adoption of the agreement. On December 12, 2021, Jamie Weinstein resigned from position as a member of the board of directors, as he no longer supported the business combination. The transaction is expected to close in the fourth quarter of 2021. Citigroup Inc. (NYSE:C) acted as exclusive financial advisor and James T. Barrett and Eric J. Carlson of Goodwin Procter LLP acted as legal counsels to Gelesis. John Delgado and Robin Tang of UBS acted as financial advisor and Ernest Wechsler, Christopher Auguste, Adi Herman, Ilya Kontorovich, Jackson D. Mann, Alan R. Friedman, Harry Rubin, Irena Royzman, Marcus A. Colucci, Marissa J. Holob, Avram J. Cahn, Robert N. Holtzman, Kelly Schreiber, Barry Herzog, Helayne Oberman Stoopack and Charles S. Warren of Kramer Levin Naftalis & Frankel LLP acted as legal advisors to Capstar. BTIG, LLC also acted as financial advisor to Capstar. Michael J. Blankenship of Winston & Strawn represented the placement agents, Citigroup Global Markets Inc. and UBS Investment Bank. Mark Zimkind of Continental Stock Transfer & Trust Company acted as transfer agent to Capstar. MacKenzie Partners, Inc. acted as proxy solicitor to Capstar for a fee of $17,500, plus disbursements for such services. Marcum LLP provided independent auditor’s report on financials of Capstar while KPMG LLP provided independent auditor’s report on financials of Gelesis.